156 related articles for article (PubMed ID: 37699957)
1. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease.
Yang D; Xie H; Wu S; Ying C; Chen Y; Ge Y; Yao R; Li K; Jiang Z; Chen G
NPJ Parkinsons Dis; 2023 Sep; 9(1):132. PubMed ID: 37699957
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
[TBL] [Abstract][Full Text] [Related]
4. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament light as a biomarker for motor decline in Parkinson's disease.
Liu Y; Dou K; Xue L; Li X; Xie A
Front Neurosci; 2022; 16():959261. PubMed ID: 36117629
[TBL] [Abstract][Full Text] [Related]
6. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
[TBL] [Abstract][Full Text] [Related]
8. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
[TBL] [Abstract][Full Text] [Related]
9. Blood Neurofilament Light Chain in Parkinson's Disease: Comparability between Parkinson's Progression Markers Initiative (PPMI) and Asian Cohorts.
Chen JH; Chan L; Chung CC; Bamodu OA; Hong CT
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768602
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
11. Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.
Ou R; Liu K; Lin J; Yang T; Xiao Y; Wei Q; Hou Y; Li C; Zhang L; Jiang Z; Zhao B; Chen X; Song W; Wu Y; Shang H
J Neurol; 2024 Apr; 271(4):1837-1843. PubMed ID: 38063869
[TBL] [Abstract][Full Text] [Related]
12. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
13. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
14. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
[TBL] [Abstract][Full Text] [Related]
15. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
16. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease.
Batzu L; Rota S; Hye A; Heslegrave A; Trivedi D; Gibson LL; Farrell C; Zinzalias P; Rizos A; Zetterberg H; Chaudhuri KR; Aarsland D
NPJ Parkinsons Dis; 2022 Nov; 8(1):154. PubMed ID: 36371469
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
[TBL] [Abstract][Full Text] [Related]
18. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
20. The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson's disease.
Teng X; Mao S; Wu H; Shao Q; Zu J; Zhang W; Zhou S; Zhang T; Zhu J; Cui G; Xu C
J Neurochem; 2023 Apr; 165(2):268-276. PubMed ID: 36776136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]